Projecten
UPGRADE: Unlocking Precision Gene Therapy Vrije Universiteit Brussel
Lungtarget KU Leuven
Epigenetische regulatie van multipel myeloom cellen: identificatie van potentiële biomarkers en nieuwe combinatie therapieën. Vrije Universiteit Brussel
"Dosimetrie-aspecten van 225-Actinium voor toepassingen in moleculaire alfa-therapie" KU Leuven
Radionucliden therapie, genaamd Targeted RadioNuclide Therapy (TRNT), is een veelbelovende behandeling voor verspreide en gemetastaseerde ziekten gebruik makend van een vector gelabeld met een radionuclide die een toxisch stralingsniveau op een specifieke locatie aflevert. DOTATATE gelabeld met bèta-emitter radionucliden is op grote schaal in de kliniek gebruikt voor peptide receptor radionuclide-therapie (PRRT), meestal in de vorm van ...
B-specific: B-celgerelateerde gen- en eiwitmarkers met prognostische en therapeutische waarde voor hart-en vaatziekten KU Leuven
Atherosclerosis is the major underlying condition of cardiovascular disease (CVD) and one the leading causes of mortality. Rupture or erosion of atherosclerotic lesions can lead to acute cardiovascular events, such as myocardial infarction and stroke, making biomarkers to diagnose patients at risk for these events and develop tailored preventive interventions, an urgent need. Although atherosclerosis is a chronic inflammatory disease, ...
Het gentherapie-innovatietrainingsnetwerk KU Leuven
Gene therapy has transitioned from a distant hope to reality. To date 3 rAAV gene therapies are approved in the EU, >30 phase III clinical trials ongoing, and exciting developments in therapeutic gene editing in the pipeline. However, fundamental limitations in the bioprocessing of gene therapy vectors limit broader application. Manufacturing is not automated, with an open process environment, limited scalability and robustness, and ...
Metrologie voor opkomende gerichte alfatherapieën KU Leuven
Targeted alpha therapy (TAT) is a rapidly growing cancer treatment modality, whereby alpha-emitting radiopharmaceuticals selectively target tumours whilst minimising the radiation to healthy tissues. Presently only 223RaCl2 has regulatory approval, but its success resulted in unprecedented levels of interest and investment in TAT for a variety of cancers. It is showing promising efficacy and increased survival in clinical trials; however, ...
Nieuwe diagnostische en therapeutische benadering van inflammatoire darmaandoeningen op basis van functionele karakterisering van patiënten: de CrUCCial-index KU Leuven
The clinical phenotype and the outcome of Crohn's disease (CD) and ulcerative colitis (UC), the opposite ends of chronic inflammatory bowel diseases (IBD), are heterogeneous and represent the result of a complex interplay of the gut microbiome with the immune system in genetically predisposed individuals. Disease management is much less heterogeneous as all patients are treated using non-specific anti-inflammatory agents, and only 30-50% ...